Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma

Open access
O'Donnell, Elizabeth K., Laubach, Jacob P., Yee, Andrew J., Chen, Tianqi, Huff, Carol Ann, Basile, Frank G., Wade, Philip M., Paba‐Prada, Claudia E., Ghobrial, Irene M., Schlossman, Robert L., Burke, Jill N., Harrington, Cynthia C., Lively, Kathleen J., Lyons, Hannah F., Munshi, Nikhil C., Anderson, Kenneth C., Trippa, Lorenzo, Richardson, Paul G., Raje, Noopur S. · 2018 · British Journal of Haematology

Abstract

We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant‐ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide‐bortezomib‐dexamethasone (RVD lite) in this population and was administered over a 35‐day cycle. Lenalidomide 15 mg was given orally on days 1–21; bortezomib 1·3 mg/m 2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression‐free survival (PFS) and overall survival (OS). Fifty‐three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73 years (range 65–91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35·1 months (95% confidence interval 30·9–not reached) and median OS was not reached at a median follow‐up of 30 months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well‐tolerated and highly effective regimen, with robust PFS and OS, in the transplant‐ineligible MM population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.15261

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 166

Metadata

Authors
O'Donnell, E. K., Laubach, J. P., Yee, A. J., Chen, T., Huff, C. A., Basile, F. G., Wade, P. M., Paba‐Prada, C. E., Ghobrial, I. M., Schlossman, R. L., Burke, J. N., Harrington, C. C., Lively, K. J., Lyons, H. F., Munshi, N. C., Anderson, K. C., Trippa, L., Richardson, P. G., & Raje, N. S.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2018-05-08
Volume
182
Issue
2
Pages
222-230
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2802890120
Cited by
166
References
6
FWCI
11.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma. https://app.cochat.ai/papers/10.1111/bjh.15261
The paper
O'Donnell, E. K., Laubach, J. P., Yee, A. J., Chen, T., Huff, C. A., Basile, F. G., Wade, P. M., Paba‐Prada, C. E., Ghobrial, I. M., Schlossman, R. L., Burke, J. N., Harrington, C. C., Lively, K. J., Lyons, H. F., Munshi, N. C., Anderson, K. C., Trippa, L., Richardson, P. G., & Raje, N. S. (2018). A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.15261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.